Cargando…
Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
Glioblastoma (GBM) is inevitably refractory to surgery and chemoradiation. The hope for immunotherapy has yet to be realised in the treatment of GBM. Immune checkpoint blockade antibodies, particularly those targeting the Programme death 1 (PD-1)/PD-1 ligand (PD-L1) pathway, have improved the progno...
Autores principales: | Adhikaree, Jason, Moreno-Vicente, Julia, Kaur, Aanchal Preet, Jackson, Andrew Mark, Patel, Poulam M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072315/ https://www.ncbi.nlm.nih.gov/pubmed/31973059 http://dx.doi.org/10.3390/cells9020263 |
Ejemplares similares
-
Impaired circulating myeloid CD1c+ dendritic cell function in human glioblastoma is restored by p38 inhibition – implications for the next generation of DC vaccines
por: Adhikaree, Jason, et al.
Publicado: (2019) -
Barriers to overcoming immunotherapy resistance in glioblastoma
por: Gillette, Julia S., et al.
Publicado: (2023) -
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
por: Pearson, Joshua R. D., et al.
Publicado: (2020) -
Metabolic Barriers to Glioblastoma Immunotherapy
por: Choudhary, Nikita, et al.
Publicado: (2023) -
Overcoming delivery barriers in immunotherapy for glioblastoma
por: Rui, Yuan, et al.
Publicado: (2021)